In the last trading session, 0.1 million shares of the Zenas Biopharma Inc (NASDAQ:ZBIO) were traded. Most recently the company’s share price was $11.43, and it changed around -$0.02 or -0.17% from the last close, which brings the market valuation of the company to $478.16M. ZBIO currently trades at a discount to its 52-week high of $26.25, offering almost -129.66% off that amount. The share price’s 52-week low was $5.83, which indicates that the current value has risen by an impressive 48.99% since then.
Zenas Biopharma Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ZBIO as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight.
Zenas Biopharma Inc (NASDAQ:ZBIO) trade information
Instantly ZBIO has showed a red trend with a performance of -0.17% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 11.84 on recent trading dayincreased the stock’s daily price by 3.46%. The company’s shares are currently up 39.56% year-to-date, but still up 9.17% over the last five days. On the other hand, Zenas Biopharma Inc (NASDAQ:ZBIO) is 14.53% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $35, which translates to bulls needing to increase their stock price by 67.34% from its current value. Analyst projections state that ZBIO is forecast to be at a low of $35 and a high of $35.
Zenas Biopharma Inc earnings are expected to increase by 65.44% in 2025, but the outlook is positive 32.20% per year for the next five years.
ZBIO Dividends
Zenas Biopharma Inc’s next quarterly earnings report is expected to be released in June.
Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund and Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 934.8 shares worth $10.68 million, making up 2.23% of all outstanding shares. On the other hand, Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund held roughly 818.51 shares worth around $9.36 million, which represents about 1.96% of the total shares outstanding.
